Commercial Development: In August 2025, Jocasta Neuroscience raised $35 million in Series A funding to advance JN-0413, a proprietary -klotho formulation, through Phase 1 trials with IND submission planned for Q4 2026
Statements on this page have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease
This process is particularly important within the liver, where glutathione contributes to Phase II detoxification pathways and helps protect cells from oxidative injury during normal metabolic activity
7-Ketocholesterol induces oxiapoptophagy and inhibits osteogenic differentiation in mc3t3-E1 cells
Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression
Nanoparticles comprise at least one hydrophobic, water-insoluble and water-indispersible polymer or copolymer emulsified in a solution or aqueous dispersion of surfactants, phospholipids or fatty acids
